CL
GALT icon

Croft-Leominster’s Galectin Therapeutics GALT Stock Holding History

Croft-Leominster’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-30,000
Closed -$42K – 164
2016
Q1 		$42K Hold
30,000
– – 0.01% 163
2015
Q4 		$49K Hold
30,000
– – 0.01% 174
2015
Q3 		$70K Hold
30,000
– – 0.02% 175
2015
Q2 		$82K Buy
+30,000
New +$90.4K 0.02% 185

Other funds holding GALT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Croft-Leominster's GALT Position: Q2 2016 in Review

Croft-Leominster sold out of Galectin Therapeutics (GALT) in Q2 2016, closing a stake of 30,000 shares — an estimated $42K sold.

Croft-Leominster first reported a position in GALT in Q2 2015 and held it in 4 quarters. The position peaked at $82K in Q2 2015. 51 funds tracked by Wall St. Rank hold GALT as of Q2 2016.

  • Croft-Leominster reported no remaining Galectin Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Croft-Leominster sold 30,000 Galectin Therapeutics shares in Q2 2016, an estimated $42K.
  • Croft-Leominster first reported a position in Galectin Therapeutics in Q2 2015 and held it in 4 quarters.
  • Croft-Leominster's Galectin Therapeutics position peaked at $82K in Q2 2015.
  • 51 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2016.

Based on Croft-Leominster's 13F filing for Q2 2016, filed 12 Aug 2016.